45170-31-8

Basic information

• Product Name: Boc-N-methyl-L-valine
• Synonyms: BOC-N-METHYL-L-VAL-OH;BOC-N-METHYL-L-VALINE;BOC-N-ME-VALINE;BOC-N-ME-VAL-OH;BOC-MEVAL-OH;BOC-N-ALPHA-METHYL-L-VALINE;BOC-L-MEVAL-OH;N-ALPHA-T-BOC-N-ALPHA-METHYL-L-VALINE
• CAS NO: 45170-31-8
• Molecular Formula: C₁₁H₂₁NO₄
• Molecular Weight: 231.29
• Product Categories: Valine [Val, V];N-Methyl Amino Acids;Boc-Amino acid series;amino acids
• Mol File: 45170-31-8.mol
• Article Data: 54

Chemical Properties

• Melting Point: 45-60°C
• Boiling Point: 322.4 °C at 760 mmHg
• Flash Point: 148.8 °C
• Appearance: /Solid
• Density: 1.069 g/cm³
• Vapor Pressure: 5.74E-05mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Store at RT.
• Solubility: Chloroform (Slightly), Ethanol (Slightly), Methanol (Slightly)
• PKA: 4.03±0.10(Predicted)
• BRN: 2646180
• CAS DataBase Reference: Boc-N-methyl-L-valine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-N-methyl-L-valine(45170-31-8)
• EPA Substance Registry System: Boc-N-methyl-L-valine(45170-31-8)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 45170-31-8(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

N-Boc-N-methyl-L-valine is an amino acid derived compound that functions as a useful pharmaceutical intermediate and also employed as a reagent used in organic synthesis. It is used in the synthesis of lactam analog of actinomycin D, a potential antitumor chemotherapeutic agent.

InChI:InChI=1/C11H21NO4/c1-7(2)8(9(13)14)12(6)10(15)16-11(3,4)5/h7-8H,1-6H3,(H,13,14)/t8-/m1/s1

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 2480-23-1 N-methyl-L-valine 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 13734-41-3 t-Boc-L-valine 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 640-68-6 D-Val-OH 
• 24424-99-5 di-tert-butyl dicarbonate 
• 22838-58-0 Boc-D-Val-OH 
• 124-38-9 carbon dioxide 
• 140175-19-5 Methyl-((S)-2-methyl-1-tributylstannanyl-propyl)-carbamic acid tert-butyl ester 
• 24164-06-5 methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-methylbutanoate 
• 58561-04-9 N-tert-butoxycarbonyl-L-valine methyl ester 
• 6306-52-1 L-valine methylester hydrochloride 

Downstream Products

• 81135-38-8 benzyl (2S)-3-methyl-2-(methylamino)butanoate 
• 89536-87-8 H-N-Me-D-Val-OBzl 
• 863781-50-4 Boc-Val(N-Me)-Leu-Phe-OMe 
• 89536-89-0 benzyl (2S)-3-methyl-2-(methylamino)butanoate hydrochloride 
• 1271141-46-8 methyl (S)-2-(2-((1H-Indol-4-yl)(methyl)amino)-3-methylbutanamido)acrylate 
• 1097985-47-1 methyl (2S,5R)-2-isopropyl-1-methyl-3-oxo-2,3,4,5,6,8-hexahydro-1H-[1,4]diazonino[7,6,5-cd]indole-5-carboxylate 
• 1418290-17-1 (S)-benzyl 2-(2-(2-(tert-butoxycarbonylamino)-N-methylacetamido)-3-methyl-butanamido)benzoate 
• 1418290-19-3 (S)-benzyl 2-(2-(2-amino-N-methylacetamido)-3-methylbutanamido)benzoate 2,2,2-trifluoroacetate 
• 1418290-15-9 (S)-benzyl 2-(2-(2-(2-(dimethylamino)benzamido)-N-methylacetamido)-3-methylbutanamido)benzoate 
• 106283-19-6 (S)-2-(2-(2-(2-(dimethylamino)benzamido)-N-methylacetamido)-3-methylbutanamido)benzoic acid 
• 203646-36-0 O-(tert-butoxycarbonyl)-N-methylvalyl-N-(benzyloxycarbonyl)threonyl-D-phenylalaninylprolylsarcosine tert-butyl ester 

Relevant articles and documents

Synthetic studies on quinoxaline antibiotics: II. Synthesis of triostin A

Triostin A, a cyclic octadepsipeptide, was synthesized with Z-D-Ser[Boc-Ala-MeCys(Bzl)-MeVal]-OH and Z-n-Ser[H-Ala-MeCys(Bzl)-MeVal]-OTce as key intermediates. The synthetic antibiotic was compared with natural triostin A in terms of chromatographic behaviors, NMR spectra, and antomicrobial activity to establish their identity. The NMR data on S,S'-dibenzyldihydrotriostin A showed that this intermediate lacking the disulfide linkage also existed as two conformers in chloroform. This observation excludes the possibility that the conformer equilibrium known to occur with triostin A is a consequence of the reversed chirality of the disulfide bond. Triostin A, a cyclic octadepsipeptide, was synthesized with Z-D-Ser left bracket Boc-Ala-MeCys(Bzl)-MeVal right bracket -OH and Z- D-Ser left bracket H-Ala-MeCys(Bzl)-MeVal right bracket -OTce as key intermediates. The synthetic antibiotic was compared with natural triostin A in terms of chromatographic behaviors, NMR spectra, and antimicrobial activity to establish their identity. The NMR data on S,S prime -dibenzyldihydrotriostin A showed that this intermediate lacking the disulfide linkage also existed as two conformers in chloroform. This observation excludes the possibility that the conformer equilibrium known to occur with triostin A is a consequence of the reversed chirality of the disulfide bond.

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.